Company Overview Our People Senior Management J. Donald deBethizy, Ph.D. Merouane Bencherif, M.D., Ph.D. Jeffrey P. Brennan William S. Caldwell, Ph.D. Geoffrey C. Dunbar, M.D. Alan A. Musso, C.P.A., C.M.A. Peter A. Zorn, Esq. Mauri K. Hodges, C.P.A., C.C.P. Karen A. Hicks Board of Directors Mark Skaletsky (Chairman) Committee Composition M. James Barrett, Ph.D. Charles A. Blixt, Esq. Julia R. Brown G. Steven Burrill J. Donald deBethizy, Ph.D. Errol B. De Souza, Ph.D. Alan W. Dunton, M.D. John P. Richard Ralph Snyderman, M.D. Our History Our Community Winston-Salem Business & Industry Winston-Salem Amenities Targacept in the Community Activities Company Awards Product Pipeline TC-5214 - Major Depressive Disorder TC-5619 - Residual Symptoms in Schizophrenia, Alzheimer’s Disease and ADHD AZD3480 - ADHD AZD1446 - Alzheimer’s Disease Science & Technology Targacept's Solution Neuronal Nicotinic Receptors (NNRs) NNRs: How They Work NNRs: Therapeutic Effects NNR Research Capabilities Patents Scientific Articles Research Grants Drug Discovery Pentad™        Business Development Licensing Opportunities Investor Relations Company Profile Corporate Governance 2011 Annual Meeting Stock Information SEC Filings Analyst Coverage Press Releases Annual Reports Investor Calendar Clinical and Scientific Calendar Board of Directors Senior Management Investor Contact Information Request Form Investor FAQ Email Alerts Policy on Rumors Newsroom Press Releases Online Press Kit Event Calendar Careers Current Opportunities Our People Our Values Our Benefits ©2012 Targacept, Inc. Terms of Use Home Directions Contact Site Map  Go